Cody Shandraw is investing in every vertical of the psychedelic space, with particular regards to the real estate needed for clinical infrastructure as psychedelic medicines start to get rolled out in the near future. We discuss his approach to due diligence, the overall state of the psychedelic medicine landscape, and why you can't truly blind a psychedelic clinical trial.

Hosted on Acast. See acast.com/privacy for more information.